Contact UsInvestorsCareersMediaScienceContact Us
HomeProductsPrescription MedicinesFragmin

This page is intended as reference information for the general public in Great Britain.

Fragmin® (dalteparin sodium)

What is Fragmin and what is it used for?

Fragmin is a solution for injection and it belongs to a group of medicines called low molecular weight heparins (LMWH) or antithrombotics.  These medicines help prevent the formation of blood clots by thinning the blood.

Venous thromboembolism (VTE) is a condition where blood clots develop in the legs (deep vein thrombosis, DVT) or the lungs (pulmonary embolism, PE), e.g. after surgery, prolonged bed rest or in patients with certain types of cancer.

Fragmin can be used in many different conditions:

  • In adults, to prevent blood clots (venous thromboembolism) forming before and after an operation

  • Prevention of deep vein thrombosis in adult patients bedridden due to a medical condition but not limited to, for example heart failure and respiratory failure

  • To treat blood clots in adults

  • To treat blood clots in certain types of cancer and prevent their recurrence in adults

  • Fragmin may be used to treat a condition known as unstable angina and non-Q wave myocardial infraction (unstable coronary artery disease) in adult patients who are taking aspirin
  • Fragmin may be used in adult patients having haemodialysis or haemofiltration. Fragmin prevents blood clots being formed in the tubes of the equipment
  • Treatment of blood clots in the veins (venous thromboembolism or VTE) in children and adolescents 1 month of age and older

Fragmin is a Prescription Only Medicine.

Reference Information

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Fragmin these can be found at the electronic Medicines Compendium (eMC).

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

PP-FRA-GBR-0360 / September 2023
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.